Company Monitoring Page for Bluebird-Bio

latest headlines for company on cafepharma

Two Sickle Cell Disease Gene Therapies May Soon Be Approved By FDA
Forbes
Thu, 11/2/23 - 05:07 pm
Tags:
sickle cell disease, gene therapy, lovo-cel, exa-cel, Vertex Pharmaceutical, CRISPR Therapeutics, Bluebird Bio
Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved
Reuters
Mon, 10/30/23 - 10:23 am
Tags:
Bluebird Bio, priority review vouchers, sickle cell disease, gene therapy
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
Tags:
FDA, Alnylam, Onpattro, ATTR amyloidosis, Vertex Pharmaceuticals, CRISPR Therapeutics, exa-cel, Bluebird Bio, Zynteglo, sickle cell disease, Bristol Myers Squibb, 2seventy bio, Abecma, Multiple Myeloma, Amgen, Lumakras, non-small cell lung cancer, Pfizer, estrasimod, ulcerative colitis
Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona
Fierce Pharma
Thu, 09/28/23 - 10:27 am
Tags:
Bluebird Bio, gene therapy, Lonza, drug manufacturing, CDMOs
Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm
BioSpace
Wed, 08/16/23 - 11:09 pm
Tags:
Bluebird Bio, sickle cell disease, lovo-cel, FDA
Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears
Fierce Pharma
Tue, 08/8/23 - 11:33 am
Tags:
Bluebird Bio, Zynteglo, Skysona, FDA, sickle cell disease, gene therapy
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
Reuters
Fri, 07/14/23 - 10:07 am
Tags:
ICER, gene therapy, Vertex Pharmaceuticals, CRISPR Therapeutics, Bluebird Bio, drug pricing, sickle cell disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
Tags:
FDA, Eisai, Biogen, Leqembi, Alzheimer's disease, SAGE Therapeutics, zuranolone, postpartum depression, major depressive disorder, Roche, Tecentriq, non-small cell lung cancer, CRISPR Therapeutics, Bluebird Bio, lovo-cel, exa-cel, BrainStorm Cell Therapeutics, NurOwn
Bluebird, playing catch-up, gets decision date for sickle cell gene therapy
BioPharma Dive
Wed, 06/21/23 - 11:49 am
Tags:
Bluebird Bio, gene therapy, sickle cell disease, lovo-cel, FDA
Death triggers pause of 2seventy CAR-T cell therapy leukemia trial
Fierce Biotech
Wed, 06/14/23 - 10:18 am
Tags:
2seventy bio, Bluebird Bio, CAR-T, patient death, clinical trials, AML
Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch
Forbes
Wed, 05/3/23 - 11:48 am
Tags:
gene therapy, drug approvals, Biomarin, Bluebird Bio, FDA
Bluebird Bio submits BLA for sickle cell disease gene therapy
Biopharma Reporter
Mon, 04/24/23 - 11:39 am
Tags:
Bluebird Bio, sickle cell disease, lovo-cel, FDA
Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced
Endpoints
Wed, 03/29/23 - 04:04 pm
Tags:
Bluebird Bio, sickle cell disease, gene therapy, FDA, lovo-cel
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
BioPharma Dive
Tue, 02/21/23 - 04:37 pm
Tags:
Medicaid, sickle cell disease, gene therapies, Bluebird Bio, Vertex Pharmaceuticals, CRISPR Therapeutics
Bluebird hopes to raise upwards of $100M by selling shares
Endpoints
Wed, 01/18/23 - 12:08 pm
Tags:
Bluebird Bio
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Motley Fool
Wed, 01/18/23 - 09:50 am
Tags:
Moderna Therapeutics, RSV, Bluebird Bio, NASDAQ
FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies
NASDAQ
Mon, 12/19/22 - 10:59 am
Tags:
Bluebird Bio, FDA, clinical trials, lovo-cel, sickle cell disease
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
Tags:
ASH 2022, JNJ, talquetamab, Multiple Myeloma, Argenx, Bluebird Bio, Vyvgart, ITP
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
Fierce Pharma
Sun, 12/11/22 - 01:34 pm
Tags:
Bluebird Bio, ASH 2022, Zynteglo, sickle cell disease, gene therapy, lovo-cel
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Benzinga
Wed, 11/30/22 - 10:47 am
Tags:
Bluebird Bio, priority review vouchers, FDA, Argenx

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.